IFNA1 and cancer: We predict that recombinant IFN-I, together with new products affecting endogenous IFN production or response, will find an important place in future combination therapies of cancer, provided that further preclinical and clinical studies will address the critical issues regarding optimal modalities for delivering the right amount of the cytokines at the right time, in the right place, and in the right patients.